Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Rui-Inno Pharma”) recently announced that its novel dermatological drug, MDI-1228 mesylate gel, has received U.S. FDA IND Safe To Proceed letter, officially advancing to a Phase 2 clinical trial for the treatment of chronic ulcerative diabetic foot (diabetic foot) caused by diabetes.
Rui-Inno Pharma plans to conduct a multicenter, open-label clinical trial in the United States to evaluate the efficacy and safety of MDI-1228 in diabetic foot patients.
According to the company’s press release, this marks the first time a pharmaceutical company from mainland China has received approval to conduct clinical research in the U.S. for this indication, representing a significant milestone in the development of new drugs for diabetic foot ulcers.
Rui-Inno is focused on JAK inhibitor development for chronic wounds and plans to expand its indications to include bed ulcers, severe burns, and other related conditions.